AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
Active, not recruiting
- Conditions
- Lung Malignancy
- Interventions
- Other: Participant Cohort
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT05817110
- Locations
- 🇹🇷
Research Site, Mersin, Turkey
An ADME Study of [14C]AZD0780 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: AZD0780 tabletDrug: [14C]AZD0780 Solution for InfusionDrug: [14C]AZD0780 Oral Solution
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT05817461
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Active, not recruiting
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT05809934
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT05801029
- Locations
- 🇹🇭
Research Site, Songkhla, Thailand
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1
Recruiting
- Conditions
- Ovarian CancerLung Adenocarcinoma
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 396
- Registration Number
- NCT05797168
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects
Phase 1
Terminated
- Conditions
- Healthy Subjects (Indication: Asthma)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT05794672
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT05790304
- Locations
- 🇸🇰
Research Site, Bratislava, Slovakia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05787002
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3
Recruiting
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4300
- Registration Number
- NCT05774951
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
Completed
- Conditions
- Advanced Ovarian Cancer
- Interventions
- Other: None (Observational Study)
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05775549
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath